Use of Prolactin Receptor Antagonist to Better Understand Prolactin Regulation of Pituitary Homeostasis

Jimena Ferraris^a Sophie Bernichtein^b Daniel Pisera^a Vincent Goffin^b

^aInstitute of Biomedical Research, School of Medicine, University of Buenos Aires-CONICET, Buenos Aires, Argentina; ^bInserm, Unit 845, Research Center Growth and Signaling, Prolactin/Growth Hormone Pathophysiology Laboratory, University Paris Descartes, Sorbonne Paris Cité, Faculty of Medicine, Necker Site, Paris, France

Key Words

Prolactin · Del1-9-G129R-hPRL · Prolactin receptor antagonist · Pituitary · Apoptosis · Proliferation

Abstract

The anterior pituitary is permanently regulated by processes of apoptosis and proliferation in order to maintain tissue homeostasis. Several factors have been implicated in this regulation and lately, prolactin (PRL) has been included into that list. However, since PRL is secreted by anterior pituitary lactotrophs, the actual outcome of its autocrine/paracrine actions on pituitary cells has remained difficult to assess. The availability of the pure PRL receptor antagonist Del1-9-G129R-hPRL has been helpful to circumvent this problem. While PRL has been traditionally associated with increased cell proliferation, recent studies revealed that this hormone actually induces apoptosis and decreases proliferation of anterior pituitary cells, by mechanisms involving the PRL receptor. The aim of this short review is to overview our current understanding of the regulation of pituitary homeostasis by PRL. Moreover, studies involving Del1-9-G129R-hPRL have helped anticipate to what extent future treatments involving PRL receptor inhibitors may interfere with processes regulated by PRL at the central level.

© 2013 S. Karger AG, Basel

Development of Prolactin Receptor Antagonists

Prolactin (PRL) was identified in the late 1920s as a hormone produced in the anterior pituitary and able to stimulate milk synthesis by the mammary gland [1, 2]. It was later shown that PRL production/secretion by the pituitary was mainly under the inhibitory control of dopamine, acting via the dopamine 2 receptor (D2R) expressed in lactotrope cells (for a review, see Freeman et al. [3]). This discovery paved the way for the development of dopamine agonists now used routinely as therapeutic inhibitors of PRL secretion in patients exhibiting pathological hyperprolactinemia [4]. Besides endocrine PRL, local PRL production has been documented in various tissues referred to as extrapituitary sites of PRL production, where the hormone is assumed to act in an autocrine/paracrine manner (for a review, see Ben-Jonathan et al. [5]). These include the breast, the prostate, the skin or cells of the immune system to cite only a few. Interestingly enough, various studies reported that the level of PRL protein expression was enhanced in tumors affecting some of these tissues, e.g. breast and prostate tumors [6, 7]. Based on its ability to stimulate proliferation of various cell types [8–10], it was then suggested that such an increased PRL expression may participate in the promo-

tion of tumor growth. However, since the regulation of PRL gene expression in extrapituitary tissues is virtually unknown, this hypothesis could not be addressed using pharmacological inhibitors able to block PRL expression in peripheral tumors. This was the rationale to develop PRL receptor (PRLR) antagonists aimed to block PRL biological actions at the level of the receptor when PRL expression cannot be targeted [6].

The PRLR belongs to the cytokine receptor superfamily, which involves non-tyrosine kinase, single-pass transmembrane chains [11]. Prolactin receptor signaling is triggered by the formation of a heterotrimeric complex involving one ligand bound to two identical receptor moieties forming a homodimer (fig. 1a). This ternary complex involves 3 intermolecular interactions called sites 1 and 2 (between PRL and each receptor) and site 3 (between the two receptors) [12]. The active complex then triggers various intracellular signaling cascades including the canonical Jak2/STAT5 pathway, MAPK, Akt and Src cascades (for a review, see Goffin et al. [6]). Similar to the development of the growth hormone receptor antagonist Somavert [13], the rational design of competitive PRLR antagonists reported by various teams has generally involved the introduction of appropriate mutations at binding site 2, which results in the functional inhibition of the interaction between PRL and one of the two receptor moieties (for a review, see Goffin et al. [14]) (fig. 1a). The lead compound that we have developed is called Del1-9-G129R-hPRL, due to the truncation of the 9 N-terminal residues and the steric hindrance introduced at position 129 (Arg substituted for Gly) [15]. The antagonistic properties of Del1-9-G129R-hPRL have been assessed by us and several collaborators using a wide panel of in vitro and in vivo assays, involving various cell types (breast, prostate, skin, neural cells, etc.) of mouse, rat or human origin [16–21]. Using pharmacological approaches to achieve acute inhibition of PRLR signaling, these studies have shown that (1) Del1-9-G129R-hPRL is devoid of residual agonism, (2) efficiently competes with exogenous PRL when added in >10-fold molar excess to compensate for its lower affinity for the PRLR, and (3) partially inhibits the actions triggered by autocrine PRL when added in high excess (at undetermined fold since in extrapituitary tissues locally produced PRL is frequently below detection limits). Due to the short half-life of the antagonist, we turned to a transgenic approach to evaluate its long-term effects in vivo. Transgenic mice expressing Del1-9-G129R-hPRL systemically (called below Tg^{Del1-9-G129R} mice) did not display gross pathological phenotypes. We noticed that 6-month-old females had

irregular reproductive cycles which tended to normalize with age [unpubl. data] but this did not significantly alter fertility. Since female mice deficient for the PRLR gene (PRLR-KO) are infertile [22], the absence of a marked reproductive phenotype of Tg^{Del1-9-G129R} females indicated that total inhibition of PRLR signaling was not achieved in these animals, as would have been expected from a competitive antagonist. This transgenic model also revealed the antitumor (antiproliferative) activity of the PRLR antagonist in the context of autocrine PRL-induced prostate tumors [23] (fig. 1b). This is to our knowledge the first molecule that has been shown to functionally counteract the actions triggered by locally produced PRL.

The effects of PRLR antagonists on various peripheral PRL target cell types/tissues as well as their potential therapeutic use as tumor growth inhibitors have been widely discussed in recent review articles [6, 7, 24]; therefore, these issues will not be considered hereafter. One of the open questions in the above context is to what extent future treatment involving PRLR signaling inhibitors may interfere with processes regulated by PRL at the central level, including PRL production per se. This question is particularly relevant since many of the feedback mechanisms regulating pituitary PRL production remain poorly understood. In contrast to other pituitary hormones that are regulated by identified peripheral secondary messenger(s), e.g. insulin-like growth factor-1, one of the major downregulators of pituitary GH secretion, such a putative factor has not yet been identified for the PRL system. Thus, the aim of this short review is to overview our current understanding of the feedback mechanisms by which PRL controls its own production and, more generally, regulates pituitary homeostasis, and to highlight, where appropriate, the added value of PRLR antagonists in advancing our knowledge.

Prolactin Actions in the Hypothalamus

Physiological adaptations to pregnancy and lactation induced by PRL involve its action at the level of the central nervous system (CNS). Prolactin acts in the forebrain subventricular zone inducing the production of neuronal progenitors that migrate to the olfactory bulb [25]. In pregnant females, this process is essential to appropriate behavioral adaptive changes in the postpartum period, required for normal offspring development (reviewed in Larsen and Grattan [26]).

In addition, PRL regulates the hypothalamic-pituitary-gonadal axis. The anovulatory effect of hyperpro-

by dopaminergic signals originating from the hypothalamus [34]. Prolactin thus participates in a short negative feedback loop by stimulating the activity of hypothalamic neuroendocrine dopaminergic neurons, and increasing dopamine release (for a review, see Freeman et al. [3]). The hypothalamus expresses the PRLR [35–37], and it was demonstrated using *in vitro* cell culture preparations of the fetal rat mediobasal hypothalamus that PRL stimulation induces expression and activity of tyrosine hydroxylase (TH) [38], the rate-limiting enzyme in catecholamine synthesis which *in vivo* eventually increases dopamine input into the anterior pituitary. The effect of PRL on hypothalamic catecholamine synthesis was significantly reduced using a 10-fold excess of Del1-9-G129R-hPRL, indicating that this action is PRLR-specific (fig. 1b) [38]. The latter study provided evidence for the usefulness of this antagonist as a molecular tool to investigate further the biological effects and mechanisms of action of PRL on hypothalamic neurons. It was next demonstrated that STAT5B was the primary mediator of PRL actions in TH-positive cells from the mediobasal fetal rat hypothalamus [39, 40] and mouse hypothalamus [40]. The involvement of STAT5B was unexpected since PRLR preferentially signals via STAT5A. Interestingly enough, although Del1-9-G129R-hPRL significantly inhibited STAT5 phosphorylation induced by PRL in TH-positive neurons, ~20% of cells remained positive for nuclear (active) STAT5 even at extremely high antagonist concentration (>100 μ M). Since these studies confirmed that Del1-9-G129R-hPRL was devoid of residual agonistic activity towards the rat PRLR even at these concentrations, this observation suggested that some TH-positive neurons may exhibit very high sensitivity to low PRL concentrations and/or resistance to PRLR signaling inhibitors [39]. This may account for the absence of detectable hyperprolactinemia in Tg^{Del1-9-G129R} mice [23] despite the clear inhibitory action of the PRLR antagonist on dopamine synthesis as demonstrated in these *in vitro* studies.

Prolactin Actions in the Pituitary

In the majority of its target tissues, most of the documented effects of PRL on cell renewal relate to the stimulation of cell proliferation (for reviews, see [3, 41, 42]). Nevertheless, PRL has also been shown to exert antiproliferative/proapoptotic actions in some specific tissues, and we and others have identified that the pituitary falls into this second category. Typical examples of these opposite effects on cell renewal are given below.

Prolactin, Proliferation and Apoptosis

Prolactin stimulates proliferation of mammary gland epithelium [43], hepatocytes [44], pancreatic beta cells [45], prostate epithelial cells [23], astrocytes [46], neurons [25] and various cells of the immune system [47]. Many of these actions are associated with adaptation to litter care, e.g. lactation and maternal behavior. Mammary gland development during pregnancy depends mainly on PRL action that induces proliferation and differentiation of the secretory epithelium, especially during lobuloalveolar differentiation [22]. After lactation, the mammary gland undergoes involution which involves cellular apoptosis induced by various signals, including a decrease in PRL-induced JAK/STAT signaling [48]. Prolactin contributes to maternal behavior by stimulating proliferation of neural stem cells in the forebrain subventricular zone, which in turn leads to increased numbers of neurons in the olfactory bulbs [25]. These actions of PRL on neurogenesis and maternal behavior have been recently reviewed by Grattan's group [26]. In the pancreas, PRL is responsible for beta cell proliferation, allowing normal glucose homeostasis during pregnancy [45].

Prolactin also controls nonreproductive actions, as in the immune system. It regulates T cell differentiation, B cell-mediated tolerance and enhances proliferative responses to several mitogens and, by a PRLR-mediated effect, PRL stimulates mitosis of normal and lymphoma-derived lymphocytes [49]. As a hallmark of PRL proliferative properties, the growth of PRL-dependent Nb2 rat lymphoma cell line has been used for three decades as the reference bioassay to measure PRL activity and concentration in biological fluids [50].

Prolactin can also induce apoptosis in many contexts, which is usually beyond the actions conventional wisdom attributes to this hormone. In the rat, the peak of circulating PRL occurring at proestrus is responsible for inducing luteolysis of the corpora lutea of the preceding cycle [51–53]. Prolactin is locally synthesized and secreted by keratinocytes in the human hair follicle and via a short loop mechanism, it induces apoptosis and inhibits proliferation of these cells [54]. Chondrocyte apoptosis is needed in the process of endochondral bone formation; PRL was shown to increase this process, which is assumed to favor bone elongation in pregnant and lactating rats [55]. It was also reported that PRL increases apoptosis of a human myeloma-derived cell line [56].

The proapoptotic actions of PRL are further supported by the fact that the canonical signaling cascade of its receptor, namely Jak2/STAT5, may in some instance lead to proapoptotic responses [3, 41, 42, 57]. For example, the

induction of apoptosis by oncostatin M (another hematopoietic cytokine structurally close to PRL) in osteosarcoma cells requires functional STAT5 to regulate Bax/Bcl-2 ratio [58]. Similarly, activation of Jak2/STAT5 pathway in rat cerebella granule neurons induces apoptosis, also by regulating the expression of Bcl-2 family proteins [59]. In fact, the ultimate effects of PRL in a given tissue depend on many parameters including the PRLR isoform(s) that is(are) expressed and the particular physiological context. As discussed below, PRL-regulated cell apoptosis is a key mechanism in pituitary homeostasis.

Prolactin and Anterior Pituitary Cell Renewal

Anterior pituitary functions are regulated by multiple signals. These involve signals originating upstream, in the hypothalamus and signals originating from downstream target organs. These messenger molecules regulate pituitary hormone secretion, but also the cellular turnover of the gland. Several factors regulate cell proliferation and apoptosis in the anterior pituitary, such as dopamine [60, 61], estradiol [62, 63], and various cytokines such as tumor necrosis factor- α [64], Fas ligand [65] and interleukin-6 [66].

Hormones secreted by pituitary cells may also act as local paracrine/autocrine factors, which is the case for PRL [67]. Prolactin receptors are expressed by anterior pituitary cells [68–71]; therefore, one of the primary target cells PRL meets once it is secreted are lactotrope cells [72]. Prolactin receptor signaling inhibits PRL synthesis at the transcriptional level in lactotrope cells, which involves specific pituitary transcription factors [73]. Also, inhibition of its own secretion [72, 74] and increased PRLR internalization [75, 76] are two other mechanisms by which PRL modulates its production, and consequently its actions at the pituitary level.

In addition to regulating its own production/secretion, PRL also regulates pituitary cell turnover. It was first proposed that, as in many tissues (see above), PRL could act as a growth factor for anterior pituitary cells [77, 78]. Since D2R KO mice develop hyperprolactinemia, pituitary hyperplasia and, finally, pituitary adenomas, it was suggested that both the lack of dopamine inhibition and stimulation of cell proliferation induced by high circulating levels of PRL were responsible for the anterior pituitary cell growth observed in these mice [79]. However, it was later observed that PRL KO [80] and PRLR KO [81] mice also exhibited anterior pituitary hyperplasia. It was concluded that activation of PRLR signaling was not involved in promoting pituitary adenoma formation. However, double PRLR/D2R KO mice develop anterior pitu-

itary hyperplasia at earlier ages and prolactinomas are larger than in single KO mice. This additive effect suggests that in fact the absence of PRLR signaling may intrinsically promote pituitary tumorigenesis, independently of dopamine action [81]. In contrast, it was observed that exogenous PRL diminishes the proliferation rate of primary cultures of lactotropes prepared from D2R KO mice [81]. However, the direct effects of PRL in anterior pituitary cells, especially lactotropes, are usually difficult to assess unequivocally since the stimulus (i.e. PRL) is intrinsically present in the system [73]. Although pituitary PRL can be controlled with dopamine analogs, the latter intrinsically affect apoptosis and proliferation in these cells [60], therefore a dopamine-independent model was needed to address such questions. We took advantage of the Del1-9-G129R-hPRL antagonist to block the actions of endogenous PRL in order to better delineate the direct (autocrine) effects of PRL on PRL-secreting cells (fig. 1b). Thanks to this unique molecular tool, we were able to show that PRL acts as a paracrine/autocrine antiproliferative and proapoptotic factor on primary cultures of male rat anterior pituitary cells, specifically but not exclusively on lactotropes [71]. These findings definitely confirmed that the pituitary hyperplasia observed in D2R KO mice is not generated by a PRL proliferative action as had been initially proposed [79]. Furthermore, the availability of Tg^{Del1-9-G129R} mice gave us the opportunity to investigate the effect of chronic blockade of PRLR signaling in mice still expressing both the PRLR and its ligand, which more closely mimics the physiological context. We observed that Del1-9-G129R-hPRL expression induced moderate pituitary hyperplasia and 15-fold increase in the anterior pituitary proliferation index. Accordingly, the pituitary weight of Tg^{Del1-9-G129R} mice was 25% higher compared to controls; direct comparison of pituitary hypertrophy induced by functional (Tg^{Del1-9-G129R}) versus genetic (PRLR KO) PRLR signaling inhibition [81] could not be made since the animals involved in the two studies were not age-matched. Taken together, these findings indicate that PRL acts as an antiproliferative factor on anterior pituitary cells.

In females, through pregnancy and lactation and during estrus, the number of anterior pituitary cells increases, mainly due to the expansion of the lactotrope population. At the end of each of these periods, apoptosis processes restore the number of cells, maintaining tissue homeostasis. In the rat, 1.5% of anterior pituitary cells are renewed daily, this turnover being higher in females than in males, and dependent on the stage of the estrous cycle [67]. In sexually mature females, hypothalamic, pituitary,

and ovarian hormones present particular profiles of secretion that defines the endocrine environment in each stage of the estrous cycle. In the rat, these cyclic changes are reflected in anterior pituitary cell turnover: proliferation takes place mainly during estrus whereas the higher rate of apoptosis occurs at proestrus [82, 83]. Changes in circulating levels of gonadal steroids that characterize each stage of the estrous cycle could be, at least in part, responsible for the cyclic changes in proliferation and apoptosis observed in the anterior pituitary [67]. During proestrus, when the peak of anterior pituitary cell apoptosis is observed [63], an increase in estradiol and PRL-circulating levels occurs in both rats [3] and mice [84, 85]. As PRL is a proapoptotic factor for anterior pituitary cells, we hypothesize that this hormone could be involved in the control of the changes that occur in the anterior pituitary gland at each estrous cycle. Our laboratories are currently investigating the pituitaries of PRLR KO mice and Tg^{Del1-9-G129R} female mice to address this hypothesis.

The molecular mechanisms by which PRL exerts proapoptotic effects to regulate pituitary cell homeostasis are currently unknown. Two major isoforms of PRLR have been reported, referred to as long and short PRLR, which display only partial overlap in their intracellular signaling capacities (reviewed in Ben-Jonathan et al. [42]). In addition, since short PRLR has been reported to exert a dominant negative effect on the ability of the long isoform to activate the Jak/STAT pathway [86, 87], the ultimate effects of PRL depend on the PRLR isoforms expressed and on their relative ratio. Prolactin regulates expression of its own receptor in several tissues, such as hypothalamus [35–37, 88], ovary [89], brain [70], fallopian tubes [90] and pancreas [91]. Anterior pituitary cells from both mice [71, 90] and rats [68, 69] express both PRLR isoforms. In male mouse pituitary, the long PRLR is the main isoform expressed, representing about 90% of total pituitary PRLR [71]. Interestingly enough, chronic expression of Del1-9-G129R-hPRL in transgenic mice leads to a 10-fold increase in long PRLR versus only a 2-fold increase of short PRLRmRNA expression, indicating that PRL regulates the expression of its receptor in an isoform-specific manner [71]. In female rats, PRLR isoform expression in the pituitary varies during the estrous cycle [69], suggesting that gonadal steroids are involved in its regulation. In prepubertal rat pituitary, the short PRLR isoform was reported to be the main isoform expressed that was further increased by PRL treatment [90]. In adult female rat pituitary, although the long PRLR isoform is the most abundant at both proestrus and diestrus, long PRLR expression increases 1.5-fold at diestrus compared to pro-

estrus [69]. Nagano and Kelly [69] proposed that PRLR expression at proestrus may be negatively regulated by the proestrus surge of PRL acting directly or indirectly at the pituitary level. In fact, ovariectomy, which decreases circulating levels of PRL, was reported to increase PRLR expression [70]. Our ongoing studies using Tg^{Del1-9-G129R} female mice suggest that functional blockade of PRLR signaling alters expression of anterior pituitary PRLR in both isoform-specific and estrous cycle stage-specific manner. Taken together, these studies suggest that the regulation of PRLR expression may be one of the mechanisms by which PRL controls pituitary (lactotrope) cell turnover and homeostasis, although downstream signaling pathways involved remain to be investigated.

Conclusion

In summary, PRL exerts proapoptotic and antiproliferative effects which are critical to maintain pituitary cell homeostasis. Deficiencies in PRLR signaling lead to the accumulation of anterior pituitary cells that are not removed and continue to proliferate, which results in pituitary hyperplasia. As pituitary adenomas are the most common intracranial tumors, understanding the physiology of anterior pituitary cell turnover is useful to better understand prolactinoma pathogenesis and to design new treatments. Furthermore, these studies also suggest that therapeutic inhibition of PRLR signaling in the context of peripheral tumors (e.g. breast or prostate cancer), using PRLR antagonists or blocking antibodies [92], should take into account potential side effects of such drugs on pituitary cell homeostasis.

Acknowledgements

The authors thank Paul Kelly and Charlotte Sumida for critical reading of the manuscript.

References

- 1 Stricker P, Grueter R: Action du lobe antérieur de l'hypophyse sur la montée laiteuse. *C R Soc Biol* 1928;99:1978–1980.
- 2 Riddle O, Bates RW, Dykshorn SW: The preparation, identification and assay of prolactin – a hormone of the anterior pituitary. *Am J Physiol* 1933;105:191–216.
- 3 Freeman ME, Kanyicska B, Lerant A, Nagy G: Prolactin: structure, function, and regulation of secretion. *Physiol Rev* 2000;80:1523–1631.

- 4 Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. *Endocr Rev* 2006;27:485–534.
- 5 Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW: Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. *Endocr Rev* 1996;17:639–669.
- 6 Goffin V, Bernichtein S, Touraine P, Kelly PA: Development and potential clinical uses of human prolactin receptor antagonists. *Endocr Rev* 2005;26:400–422.
- 7 Goffin V, Hoang DT, Bogorad RL, Nevalainen MT: Prolactin regulation of the prostate gland: a female player in a male game. *Nat Rev Urol* 2011;8:597–607.
- 8 Brockman JL, Schroeder MD, Schuler LA: PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. *Mol Endocrinol* 2002;16:774–784.
- 9 Shiu RP, Elsholtz HP, Tanaka T, Friesen HG, Gout PW, Beer CT, Noble RL: Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line. *Endocrinology* 1983;113:159–165.
- 10 Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL: Prolactin and prolactin receptors are expressed and functioning in human prostate. *J Clin Invest* 1997;99:618–627.
- 11 Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shirota M, Banville D, Dusanter-Fourt I, Djiane J, Kelly PA: Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. *Cell* 1988;53:69–77.
- 12 Broutin I, Jomain JB, Tallet E, van Agthoven J, Raynal B, Hoos S, Kragelund BB, Kelly PA, Ducruix A, England P, Goffin V: Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2. *J Biol Chem* 2010;285:8422–8433.
- 13 Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. *Endocr Rev* 2002;23:623–646.
- 14 Goffin V, Tallet E, Jomain JB, Kelly PA: Development of prolactin receptor antagonists: same goal, different ways. *Rec Pat Endocr Metab Imm Drug Disc* 2007;1:41–52.
- 15 Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V: Development of pure prolactin receptor antagonists. *J Biol Chem* 2003;278:35988–35999.
- 16 Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Buben-dorf L, Goffin V, Nevalainen MT: Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. *Endocrinology* 2007;148:3089–3101.
- 17 Eyal O, Jomain JB, Kessler C, Goffin V, Handwerger S: Autocrine prolactin inhibits human uterine decidualization: a novel role for prolactin. *Biol Reprod* 2007;76:777–783.
- 18 Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE, Liu DX: The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells. *Int J Oncol* 2012;41:2285–2295.
- 19 Pathipati P, Gorba T, Scheepens A, Goffin V, Sun Y, Fraser M: Growth hormone and prolactin regulate human neural stem cell regenerative activity. *Neuroscience* 2011;190:409–427.
- 20 Scotland PE, Patil M, Belugin S, Henry MA, Goffin V, Hargreaves KM, Akopian AN: Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia. *Eur J Neurosci* 2011;34:745–754.
- 21 Ramot Y, Biró T, Tiede S, Tóth BI, Langan EA, Sugawara K, Foitzik K, Ingber A, Goffin V, Langbein L, Paus R: Prolactin – a novel neuroendocrine regulator of human keratin expression in situ. *FASEB J* 2010;24:1768–1779.
- 22 Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA: Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. *Genes Dev* 1997;11:167–178.
- 23 Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA, Goffin V: Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. *Proc Natl Acad Sci USA* 2010;107:15199–15204.
- 24 Goffin V, Touraine P, Culler MD, Kelly PA: Goffin insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? *Nat Clin Pract Endocrinol Metab* 2006;2:571–581.
- 25 Shingo T, Gregg C, Enwere E, Fujikawa H, Hassam R, Geary C, Cross JC, Weiss S: Pregnancy-stimulated neurogenesis in the adult female forebrain mediated by prolactin. *Science* 2003;299:117–120.
- 26 Larsen CM, Grattan DR: Prolactin, neurogenesis, and maternal behaviors. *Brain Behav Immun* 2012;26:201–209.
- 27 Sonigo C, Bouilly J, Carre N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N: Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. *J Clin Invest* 2012;122:3791–3795.
- 28 Larsen CM, Grattan DR: Prolactin-induced mitogenesis in the subventricular zone of the maternal brain during early pregnancy is essential for normal postpartum behavioral responses in the mother. *Endocrinology* 2010;151:3805–3814.
- 29 Hirai J, Nishita M, Nakao N, Saito TR, Tanaka M: Regulation of prolactin receptor gene expression in the rat choroid plexus via transcriptional activation of multiple first exons during postnatal development and lactation. *Exp Anim* 2013;62:49–56.
- 30 McKee DT, Poletini MO, Bertram R, Freeman ME: Oxytocin action at the lactotroph is required for prolactin surges in cervically stimulated ovariectomized rats. *Endocrinology* 2007;148:4649–4657.
- 31 Sirzen-Zelenskaya A, Gonzalez-Iglesias AE, Boutet de Monvel J, Bertram R, Freeman ME, Gerber U, Egli M: Prolactin induces a hyperpolarising current in rat paraventricular oxytocinergic neurones. *J Neuroendocrinol* 2011;23:883–893.
- 32 Helena CV, Cristancho-Gordo R, Gonzalez-Iglesias AE, Tabak J, Bertram R, Freeman ME: Systemic oxytocin induces a prolactin secretory rhythm via the pelvic nerve in ovariectomized rats. *Am J Physiol Regul Integr Comp Physiol* 2011;301:R676–681.
- 33 Poletini MO, McKee DT, Szawka RE, Bertram R, Helena CV, Freeman ME: Cervical stimulation activates A1 and locus coeruleus neurons that project to the paraventricular nucleus of the hypothalamus. *Brain Res Bull* 2012;88:566–573.
- 34 Ben-Jonathan N, Neill MA, Arbogast LA, Peters LL, Hoefer MT: Dopamine in hypophyseal portal blood: relationship to circulating prolactin in pregnant and lactating rats. *Endocrinology* 1980;106:690–696.
- 35 Pi XJ, Grattan DR: Increased prolactin receptor immunoreactivity in the hypothalamus of lactating rats. *J Neuroendocrinol* 1999;11:693–705.
- 36 Pi XJ, Grattan DR: Increased expression of both short and long forms of prolactin receptor mRNA in hypothalamic nuclei of lactating rats. *J Mol Endocrinol* 1999;23:13–22.
- 37 Pi X, Grattan DR: Expression of prolactin receptor mRNA is increased in the preoptic area of lactating rats. *Endocrine* 1999;11:91–98.
- 38 Ma FY, Grattan DR, Goffin V, Bunn SJ: Prolactin-regulated tyrosine hydroxylase activity and messenger ribonucleic acid expression in mediobasal hypothalamic cultures: the differential role of specific protein kinases. *Endocrinology* 2005;146:93–102.
- 39 Ma FY, Anderson GM, Gunn TD, Goffin V, Grattan DR, Bunn SJ: Prolactin specifically activates signal transducer and activator of transcription 5b in neuroendocrine dopaminergic neurons. *Endocrinology* 2005;146:5112–5119.
- 40 Yip SH, Eguchi R, Grattan DR, Bunn SJ: Prolactin signalling in the mouse hypothalamus is primarily mediated by signal transducer and activator of transcription factor 5b but not 5a. *J Neuroendocrinol* 2012;24:1484–1491.
- 41 Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA: Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. *Endocr Rev* 1998;19:225–268.
- 42 Ben-Jonathan N, LaPensee CR, LaPensee EW: What can we learn from rodents about prolactin in humans? *Endocr Rev* 2008;29:1–41.

- 43 Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in mammary carcinoma. *Endocr Rev* 2003;24:1–27.
- 44 Olazabal IM, Munoz JA, Rodriguez-Navas C, Alvarez L, Delgado-Baeza E, Garcia-Ruiz JP: Prolactin's role in the early stages of liver regeneration in rats. *J Cell Physiol* 2009;219:626–633.
- 45 Huang C, Snider F, Cross JC: Prolactin receptor is required for normal glucose homeostasis and modulation of beta-cell mass during pregnancy. *Endocrinology* 2009;150:1618–1626.
- 46 DeVito WJ, Okulicz WC, Stone S, Avakian C: Prolactin-stimulated mitogenesis of cultured astrocytes. *Endocrinology* 1992;130:2549–2556.
- 47 Buckley AR: Prolactin, a lymphocyte growth and survival factor. *Lupus* 2001;10:684–690.
- 48 Maroulakou IG, Oemler W, Naber SP, Klebba I, Kuperwasser C, Tschlis PN: Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. *J Cell Physiol* 2008;217:468–477.
- 49 Shelly S, Boaz M, Orbach H: Prolactin and autoimmunity. *Autoimmun Rev* 2012;11:A465–A470.
- 50 Tanaka T, Shiu RP, Gout PW, Beer CT, Noble RL, Friesen HG: A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. *J Clin Endocrinol Metab* 1980;51:1058–1063.
- 51 Gaytan F, Bellido C, Morales C, Sanchez-Criado JE: Luteolytic effect of prolactin is dependent on the degree of differentiation of luteal cells in the rat. *Biol Reprod* 2001;65:433–441.
- 52 Gaytan F, Bellido C, Morales C, Sanchez-Criado JE: Cyclic changes in the responsiveness of regressing corpora lutea to the luteolytic effects of prolactin in rats. *Reproduction* 2001;122:411–417.
- 53 Bowen JM, Keyes PL: Repeated exposure to prolactin is required to induce luteal regression in the hypophysectomized rat. *Biol Reprod* 2000;63:1179–1184.
- 54 Foitzik K, Krause K, Conrad F, Nakamura M, Funk W, Paus R: Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. *Am J Pathol* 2006;168:748–756.
- 55 Seriwatanachai D, Krishnamra N, Charoenphandhu N: Chondroregulatory action of prolactin on proliferation and differentiation of mouse chondrogenic ATDC5 cells in 3-dimensional micromass cultures. *Biochem Biophys Res Commun* 2012;420:108–113.
- 56 Gadó K, Pállinger E, Kovács P, Takács E, Szilvási I, Tóth BE, Nagy G, Domján G, Falus A: Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266. *Immunol Lett* 2002;82:191–196.
- 57 Binart N, Bachelot A, Bouilly J: Impact of prolactin receptor isoforms on reproduction. *Trends Endocrinol Metab* 2010;21:362–368.
- 58 Chipoy C, Brounais B, Trichet V, Battaglia S, Berreur M, Oliver L, Juin P, Redini F, Heymann D, Blanchard F: Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. *Oncogene* 2007;26:6653–6664.
- 59 Stankiewicz TR, Loucks FA, Schroeder EK, Nevalainen MT, Tyler KL, Aktories K, Bouchard RJ, Linseman DA: Signal transducer and activator of transcription-5 mediates neuronal apoptosis induced by inhibition of Rac GTPase activity. *J Biol Chem* 2012;287:16835–16848.
- 60 Radl DB, Ferraris J, Boti V, Seilicovich A, Sarkar DK, Pisera D: Dopamine-induced apoptosis of lactotrophs is mediated by the short isoform of D2 receptor. *PLoS One* 2011;6:e18097.
- 61 Radl DB, Zarate S, Jaita G, Ferraris J, Zaldivar V, Eijo G, Seilicovich A, Pisera D: Apoptosis of lactotrophs induced by D2 receptor activation is estrogen dependent. *Neuroendocrinology* 2008;88:43–52.
- 62 Zarate S, Jaita G, Zaldivar V, Radl DB, Eijo G, Ferraris J, Pisera D, Seilicovich A: Estrogens exert a rapid apoptotic action in anterior pituitary cells. *Am J Physiol Endocrinol Metab* 2009;296:E664–671.
- 63 Zarate S, Zaldivar V, Jaita G, Magri L, Radl D, Pisera D, Seilicovich A: Role of estrogens in anterior pituitary gland remodeling during the estrous cycle. *Front Horm Res* 2010;38:25–31.
- 64 Candolfi M, Jaita G, Zaldivar V, Zarate S, Pisera D, Seilicovich A: Tumor necrosis factor- α -induced nitric oxide restrains the apoptotic response of anterior pituitary cells. *Neuroendocrinology* 2004;80:83–91.
- 65 Jaita G, Candolfi M, Zaldivar V, Zarate S, Ferraris J, Pisera D, Castro MG, Seilicovich A: Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotrophs. *Endocrinology* 2005;146:4737–4744.
- 66 Haedo MR, Gerez J, Fuertes M, Giacomini D, Paez-Pereda M, Labeur M, Renner U, Stalla GK, Arzt E: Regulation of pituitary function by cytokines. *Horm Res* 2009;72:266–274.
- 67 Candolfi M, Zaldivar V, Jaita G, Seilicovich A: Anterior pituitary cell renewal during the estrous cycle. *Front Horm Res* 2006;35:9–21.
- 68 Morel G, Ouhit A, Kelly PA: Prolactin receptor immunoreactivity in rat anterior pituitary. *Neuroendocrinology* 1994;59:78–84.
- 69 Nagano M, Kelly PA: Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. *J Biol Chem* 1994;269:13337–13345.
- 70 Nogami H, Hoshino R, Ogasawara K, Miyamoto S, Hisano S: Region-specific expression and hormonal regulation of the first exon variants of rat prolactin receptor mRNA in rat brain and anterior pituitary gland. *J Neuroendocrinol* 2007;19:583–593.
- 71 Ferraris J, Boutillon F, Bernadet M, Seilicovich A, Goffin V, Pisera D: Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression. *Am J Physiol Endocrinol Metab* 2012;302:E356–E364.
- 72 Melmed S, Carlson HE, Briggs J, Hershman JM: Autocrine feedback of prolactin in cultured prolactin-secreting pituitary cells. *Horm Res* 1980;12:340–344.
- 73 Devost D, Boutin JM: Autoregulation of the rat prolactin gene in lactotrophs. *Mol Cell Endocrinol* 1999;158:99–109.
- 74 Herbert DC, Ishikawa H, Rennels EG: Evidence for the autoregulation of hormone secretion by prolactin. *Endocrinology* 1979;104:97–100.
- 75 Swaminathan G, Varghese B, Thangavel C, Carbone CJ, Plotnikov A, Kumar KG, Jablonski EM, Clevenger CV, Goffin V, Deng L, Frank SJ, Fuchs SY: Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. *J Endocrinol* 2008;196:R1–R7.
- 76 Djiane J, Houdebine LM, Kelly PA: Down-regulation of prolactin receptors in rabbit mammary gland: differential subcellular localization. *Proc Soc Exp Biol Med* 1981;168:378–381.
- 77 Hosojima H, Wyche JH: Prolactin control of growth and prolactin autoregulation in cultured human pituitary cells. *Horm Res* 1985;21:240–245.
- 78 Krown KA, Wang YF, Ho TW, Kelly PA, Walker AM: Prolactin isoform 2 as an autocrine growth factor for GH3 cells. *Endocrinology* 1992;131:595–602.
- 79 Saiardi A, Bozzi Y, Baik JH, Borrelli E: Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. *Neuron* 1997;19:115–126.
- 80 Cruz-Soto ME, Scheiber MD, Gregerson KA, Boivin GP, Horseman ND: Pituitary tumorigenesis in prolactin gene-disrupted mice. *Endocrinology* 2002;143:4429–4436.
- 81 Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, Asa SL, Low MJ: Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. *J Clin Invest* 2002;110:973–981.
- 82 Yin P, Arita J: Proestrous surge of gonadotropin-releasing hormone secretion inhibits apoptosis of anterior pituitary cells in cycling female rats. *Neuroendocrinology* 2002;76:272–282.
- 83 Hashi A, Mazawa S, Kato J, Arita J: Pentobarbital anesthesia during the proestrous afternoon blocks lactotroph proliferation occurring on estrus in female rats. *Endocrinology* 1995;136:4665–4671.
- 84 Flurkey K, Gee DM, Sinha YN, Wisner JR, Jr, Finch CE: Age effects on luteinizing hormone, progesterone and prolactin in proestrous and acyclic C57BL/6j mice. *Biol Reprod* 1982;26:835–846.

- 85 Michael SD: Plasma prolactin and progesterone during the estrous cycle in the mouse. *Proc Soc Exp Biol Med* 1976;153:254–257.
- 86 Jabbour HN, Kelly PA: Prolactin receptor subtypes: a possible mode of tissue specific regulation of prolactin function. *Rev Reprod* 1997;2:14–18.
- 87 Berlanga JJ, Garcia-Ruiz JP, Perrot-Applanat M, Kelly PA, Edery M: The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter. *Mol Endocrinol* 1997;11:1449–1457.
- 88 Anderson GM, Kieser DC, Steyn FJ, Grattan DR: Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol. *Endocrinology* 2008;149:1562–1570.
- 89 Bowen JM, Telleria CM, Towns R, Keyes PL: Downregulation of long-form prolactin receptor mRNA during prolactin-induced luteal regression. *Eur J Endocrinol* 2000;143:285–292.
- 90 Shao R, Nutu M, Weijdegard B, Egecioglu E, Fernandez-Rodriguez J, Tallet E, Goffin V, Ling C, Billig H: Differences in prolactin receptor (PRLR) in mouse and human fallopian tubes: evidence for multiple regulatory mechanisms controlling PRLR isoform expression in mice. *Biol Reprod* 2008;79:748–757.
- 91 Moldrup A, Petersen ED, Nielsen JH: Effects of sex and pregnancy hormones on growth hormone and prolactin receptor gene expression in insulin-producing cells. *Endocrinology* 1993;133:1165–1172.
- 92 Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, Fanidi A, Abrams TJ, Abraham JA: Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. *Mol Cancer Ther* 2013;12:295–305.